Survival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab Era

Author:

Gerson James N.1,Handorf Elizabeth1,Villa Diego2,Gerrie Alina S.2,Chapani Parv2,Li Shaoying3,Medeiros L. Jeffrey3,Wang Michael I.3,Cohen Jonathon B.4,Calzada Oscar4,Churnetski Michael C.4,Hill Brian T.5,Sawalha Yazeed5,Hernandez-Ilizaliturri Francisco J.6,Kothari Shalin6,Vose Julie M.7,Bast Martin A.7,Fenske Timothy S.8,Narayana Rao Gari Swapna8,Maddocks Kami J.9,Bond David9,Bachanova Veronika10,Kolla Bhaskar10,Chavez Julio11,Shah Bijal11,Lansigan Frederick12,Burns Timothy F.12,Donovan Alexandra M.12,Wagner-Johnston Nina13,Messmer Marcus13,Mehta Amitkumar14,Anderson Jennifer K.14,Reddy Nishitha15,Kovach Alexandra E.15,Landsburg Daniel J.16,Glenn Martha17,Inwards David J.18,Karmali Reem19,Kaplan Jason B.19,Caimi Paolo F.20,Rajguru Saurabh21,Evens Andrew22,Klein Andreas22,Umyarova Elvira23,Pulluri Bhargavi23,Amengual Jennifer E.24,Lue Jennifer K.24,Diefenbach Catherine25,Fisher Richard I.1,Barta Stefan K.1

Affiliation:

1. Fox Chase Cancer Center, Philadelphia, PA

2. BC Cancer, Vancouver, British Columbia, Canada

3. MD Anderson Cancer Center, Houston, TX

4. Emory University, Atlanta, GA

5. Cleveland Clinic Foundation, Cleveland, OH

6. Roswell Park Cancer Institute, Buffalo, NY

7. University of Nebraska Cancer Center, Omaha, NE

8. Medical College of Wisconsin, Milwaukee, WI

9. Ohio State University; Columbus, OH

10. University of Minnesota, Minneapolis, MN

11. Moffitt Cancer Center, Tampa, FL

12. Dartmouth-Hitchcock Medical Center, Lebanon, NH

13. Johns Hopkins University, Baltimore, MD

14. University of Alabama Cancer Center, Birmingham, AL

15. Vanderbilt Ingram Cancer Center, Nashville, TN

16. University of Pennsylvania, Philadelphia, PA

17. Huntsman Cancer Institute, Salt Lake City, UT

18. Mayo Clinic, Rochester, MN

19. Northwestern University, Evanston, IL

20. Case Western Reserve University, Cleveland, OH

21. University of Wisconsin, Madison, WI

22. Tufts University, Boston, MA

23. University of Vermont, Burlington, VT

24. Columbia University, New York, NY

25. New York University, New York, NY

Abstract

PURPOSE Mantle cell lymphoma (MCL) is a B-cell lymphoma characterized by cyclin D1 expression. Autologous hematopoietic cell transplantation (AHCT) consolidation after induction chemotherapy is often used for eligible patients; however, the benefit remains uncertain in the rituximab era. Herein we retrospectively assessed the impact of AHCT consolidation on survival in a large cohort of transplantation-eligible patients age 65 years or younger. PATIENTS AND METHODS We retrospectively studied transplantation-eligible adults age 65 years or younger with newly diagnosed MCL treated between 2000 and 2015. The primary objective was to assess for improved progression-free survival (PFS) with AHCT consolidation and secondarily to assess for improved overall survival (OS). Cox multivariable regression analysis and propensity score–weighted (PSW) analysis were performed. RESULTS Data were collected from 25 medical centers for 1,254 patients; 1,029 met inclusion criteria. Median follow-up for the cohort was 76 months. Median PFS and OS were 62 and 139 months, respectively. On unadjusted analysis, AHCT was associated with improved PFS (75 v 44 months with v without AHCT, respectively; P < .01) and OS (147 v 115 months with v without AHCT, respectively; P < .05). On multivariable regression analysis, AHCT was associated with improved PFS (hazard ratio [HR], 0.54; 95% CI, 0.44 to 0.66; P < .01) and a trend toward improved OS (HR, 0.77; 95% CI, 0.59 to 1.01; P = .06). After PSW analysis, AHCT remained associated with improved PFS (HR, 0.70; 95% CI, 0.59 to 0.84; P < .05) but not improved OS (HR, 0.87; 95% CI, 0.69 to 1.1; P = .2). CONCLUSION In this large cohort of younger, transplantation-eligible patients with MCL, AHCT consolidation after induction was associated with significantly improved PFS but not OS after PSW analysis. Within the limitations of a retrospective analysis, our findings suggest that in younger, fit patients, AHCT consolidation may improve PFS.

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3